Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000912282-25-000697
Filing Date
2025-06-23
Accepted
2025-06-23 08:48:00
Documents
1
Period of Report
2025-06-18

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 4846
  Complete submission text file 0000912282-25-000697.txt   6354
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Issuer) CIK: 0001662774 (see all company filings)

EIN.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 269 EAST GRAND AVE SOUTH SAN FRANCISCO CA 94080
Business Address
Hannah Brendan (Reporting) CIK: 0001929422 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38890 | Film No.: 251063089